IL304402A - A useful morph form of the at-527 hemisulfate salt - Google Patents

A useful morph form of the at-527 hemisulfate salt

Info

Publication number
IL304402A
IL304402A IL304402A IL30440223A IL304402A IL 304402 A IL304402 A IL 304402A IL 304402 A IL304402 A IL 304402A IL 30440223 A IL30440223 A IL 30440223A IL 304402 A IL304402 A IL 304402A
Authority
IL
Israel
Prior art keywords
hemi
advantageous
sulfate salt
morphic form
morphic
Prior art date
Application number
IL304402A
Other languages
English (en)
Hebrew (he)
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of IL304402A publication Critical patent/IL304402A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Thermal Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
IL304402A 2021-01-26 2023-07-11 A useful morph form of the at-527 hemisulfate salt IL304402A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163141789P 2021-01-26 2021-01-26
PCT/US2022/013953 WO2022164941A1 (en) 2021-01-26 2022-01-26 Advantageous morphic form of at-527 hemi-sulfate salt

Publications (1)

Publication Number Publication Date
IL304402A true IL304402A (en) 2023-09-01

Family

ID=82653876

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304402A IL304402A (en) 2021-01-26 2023-07-11 A useful morph form of the at-527 hemisulfate salt

Country Status (12)

Country Link
US (2) US20230365611A1 (https=)
EP (1) EP4284389A4 (https=)
JP (1) JP2024504392A (https=)
KR (1) KR20230135635A (https=)
CN (1) CN116744939A (https=)
AU (1) AU2022213335A1 (https=)
BR (1) BR112023014825A2 (https=)
CA (1) CA3173656A1 (https=)
IL (1) IL304402A (https=)
MX (1) MX2023008746A (https=)
TW (1) TW202245806A (https=)
WO (1) WO2022164941A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2022213335A1 (en) * 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
WO2024211746A1 (en) * 2023-04-06 2024-10-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Treatment of autoimmune diseases and cancer with protease inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US20180214370A1 (en) * 2017-01-31 2018-08-02 L'oreal Topcoat for long-wear lip compositions
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
JP2022510014A (ja) * 2018-12-05 2022-01-25 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のための高活性な合剤
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2022213335A1 (en) * 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt

Also Published As

Publication number Publication date
KR20230135635A (ko) 2023-09-25
JP2024504392A (ja) 2024-01-31
US20230365611A1 (en) 2023-11-16
TW202245806A (zh) 2022-12-01
EP4284389A4 (en) 2025-04-16
EP4284389A1 (en) 2023-12-06
AU2022213335A1 (en) 2023-07-27
WO2022164941A1 (en) 2022-08-04
MX2023008746A (es) 2023-08-01
CN116744939A (zh) 2023-09-12
US20260035404A1 (en) 2026-02-05
CA3173656A1 (en) 2022-08-04
BR112023014825A2 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
IL304402A (en) A useful morph form of the at-527 hemisulfate salt
ZA202007037B (en) Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
IL312564A (en) Polymorphs of the hydrochloride salt of linfarezan glurate
HUE072981T2 (hu) Azakinolinok mint CD38 gátlók
IL313548A (en) MET kinase inhibitors
GB202103774D0 (en) Detectiion of Ransomware
SI4192814T1 (sl) Zaviralci transglutaminaz
GB202411655D0 (en) Application of circHIF1a
SG11202102110PA (en) Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor
SMT202500240T1 (it) Sale di s-oxprenololo
SG11202106210QA (en) Salt of syk inhibitor and crystalline form thereof
SI4192813T1 (sl) Zaviralci transglutaminaz
PT3725786T (pt) Forma cristalina e forma salina de inibidor de tgf-bri e método de preparação das mesmas
GB202110403D0 (en) Ulodesine Salt
EP3650444B8 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
HK40104221A (en) Advantageous morphic form of at-527 hemi-sulfate salt
GB2593902B (en) Salt of a pharmaceutical compound
IL277578A (en) New salt forms of URAT-1 inhibitors
PL4192812T3 (pl) Inhibitory transglutaminaz
IL291368A (en) Inhibits expression of methadherin
GB202316444D0 (en) Salts of opicapone
CA3277900A1 (en) Salt of s-oxprenolol
GB202107612D0 (en) Inhibitors of metallo-beta-lactamases
PT4192812T (pt) Inibidores de transglutaminases
GB202004504D0 (en) Salt